SAFETY AND ACTIVITY OF SUBCUTANEOUS EPOIETIN ALPHA 20 000 IU THREE TIMES WEEKLY IN ANEMIC CANCER PATIENTS RECEIVING CHEMOTHERAPY: AN OPEN-LABEL PROSPECTIVE PILOT TRIAL


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles